Suppr超能文献

环丙沙星、左氧氟沙星或莫西沙星治疗实验性金黄色葡萄球菌角膜炎的有效性。

Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

作者信息

Dajcs Joseph J, Thibodeaux Brett A, Marquart Mary E, Girgis Dalia O, Traidej Mullika, O'Callaghan Richard J

机构信息

Department of Microbiology, Immunology, and Parasitology, LSU Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112, USA.

出版信息

Antimicrob Agents Chemother. 2004 Jun;48(6):1948-52. doi: 10.1128/AAC.48.6.1948-1952.2004.

Abstract

The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA, respectively) organisms that were either sensitive or resistant to ofloxacin. One drop of moxifloxacin (0.5%), levofloxacin (0.5%), or ciprofloxacin (0.3%) was topically applied hourly from 4 to 9 (early) or 10 to 15 (late) h postinfection. At 1 h after cessation of therapy, the corneas were harvested, and the number of CFU per cornea was determined. For the ofloxacin-sensitive strains, early treatment of MSSA or MRSA with moxifloxacin, levofloxacin, or ciprofloxacin produced approximately a 5-log decrease in CFU per cornea relative to that in untreated eyes (P </= 0.0001). For late therapy of ofloxacin-sensitive strains, moxifloxacin, levofloxacin, and ciprofloxacin produced approximately 5-, 4-, and 2- to 3-log reductions in CFU per cornea, respectively (P </= 0.0001). Early treatment of the ofloxacin-resistant strains with either moxifloxacin or levofloxacin produced a >/=4-log or >/=3-log decrease, respectively, in the MSSA or MRSA strains (P </= 0.0001), whereas ciprofloxacin treatment produced a 1-log decrease in CFU per cornea relative to that in untreated eyes (P = 0.1540). For late treatment of ofloxacin-resistant strains, levofloxacin and ciprofloxacin failed to significantly reduce the number of CFU per cornea (P >/= 0.3627), whereas moxifloxacin produced a significant reduction in CFU per cornea of approximately 1 log (P </= 0.0194). Therefore, for three of the four treatments tested, moxifloxacin demonstrated greater effectiveness than either levofloxacin or ciprofloxacin.

摘要

本研究的目的是在兔角膜炎模型中,定量比较莫西沙星、左氧氟沙星和环丙沙星对不同抗生素敏感性的金黄色葡萄球菌分离株的治疗效果水平。将大约100 CFU对氧氟沙星敏感或耐药的甲氧西林敏感或耐药金黄色葡萄球菌(分别为MSSA或MRSA)菌株经基质内注射到兔眼。在感染后4至9小时(早期)或10至15小时(晚期),每小时局部应用一滴莫西沙星(0.5%)、左氧氟沙星(0.5%)或环丙沙星(0.3%)。在治疗停止后1小时,采集角膜,并确定每个角膜的CFU数量。对于对氧氟沙星敏感的菌株,用莫西沙星、左氧氟沙星或环丙沙星早期治疗MSSA或MRSA,相对于未治疗的眼睛,每个角膜的CFU数量减少了约5个对数(P≤0.0001)。对于对氧氟沙星敏感菌株的晚期治疗,莫西沙星、左氧氟沙星和环丙沙星分别使每个角膜的CFU数量减少了约5、4和2至3个对数(P≤0.0001)。用莫西沙星或左氧氟沙星早期治疗对氧氟沙星耐药的菌株,MSSA或MRSA菌株的CFU数量分别减少了≥4个对数或≥3个对数(P≤0.0001),而环丙沙星治疗相对于未治疗的眼睛,每个角膜的CFU数量减少了1个对数(P = 0.1540)。对于对氧氟沙星耐药菌株的晚期治疗,左氧氟沙星和环丙沙星未能显著减少每个角膜的CFU数量(P≥0.3627),而莫西沙星使每个角膜的CFU数量显著减少了约1个对数(P≤0.0194)。因此,在所测试的四种治疗方法中的三种中,莫西沙星的疗效优于左氧氟沙星或环丙沙星。

相似文献

1
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Antimicrob Agents Chemother. 2004 Jun;48(6):1948-52. doi: 10.1128/AAC.48.6.1948-1952.2004.
2
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Curr Eye Res. 2006 Jan;31(1):23-9. doi: 10.1080/02713680500477321.
3
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Curr Eye Res. 2004 May;28(5):337-42. doi: 10.1076/ceyr.28.5.337.28676.
5
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
J Ocul Pharmacol Ther. 2012 Aug;28(4):420-7. doi: 10.1089/jop.2011.0229. Epub 2012 Feb 23.
7
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
J Cataract Refract Surg. 2008 Feb;34(2):295-301. doi: 10.1016/j.jcrs.2007.10.022.
8
Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis.
Cornea. 2001 Nov;20(8):878-80. doi: 10.1097/00003226-200111000-00020.

引用本文的文献

1
Sprayable ciprofloxacin-loaded poloxamer hydrogels for wound infection treatment.
J Drug Deliv Sci Technol. 2023 Nov;89. doi: 10.1016/j.jddst.2023.105000. Epub 2023 Sep 28.
3
Silica-Polymer Composites as the Novel Antibiotic Delivery Systems for Bone Tissue Infection.
Pharmaceutics. 2019 Dec 30;12(1):28. doi: 10.3390/pharmaceutics12010028.
6
Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review.
BMC Infect Dis. 2014 Mar 13;14:140. doi: 10.1186/1471-2334-14-140.
7
Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application.
Sci Pharm. 2013 Apr-Jun;81(2):591-606. doi: 10.3797/scipharm.1204-16. Epub 2013 Feb 4.
8
Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.
Int J Nanomedicine. 2012;7:1-10. doi: 10.2147/IJN.S25268. Epub 2011 Dec 30.
9
Resistance pattern of ciprofloxacin against different pathogens.
Oman Med J. 2010 Oct;25(4):294-8. doi: 10.5001/omj.2010.85.
10
Animal models of bacterial keratitis.
J Biomed Biotechnol. 2011;2011:680642. doi: 10.1155/2011/680642. Epub 2011 Jan 4.

本文引用的文献

2
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Am J Ophthalmol. 2002 Apr;133(4):463-6. doi: 10.1016/s0002-9394(02)01334-x.
3
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. doi: 10.1128/AAC.45.12.3544-3547.2001.
5
Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Ophthalmology. 2000 Aug;107(8):1497-502. doi: 10.1016/s0161-6420(00)00179-2.
7
Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak.
J Clin Microbiol. 1999 Sep;37(9):2858-62. doi: 10.1128/JCM.37.9.2858-2862.1999.
9
In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
Int J Antimicrob Agents. 1998 Apr;10(1):23-30. doi: 10.1016/s0924-8579(98)00020-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验